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Urine self-sampling for human papillomavirus (HPV)-based cervical cancer screening is a
non-invasive method that offers several logistical advantages and high acceptability, reduc-
ing barriers related to low screening coverage. This study developed and evaluated the per-
formance of a low-cost urine self-sampling method for HPV-testing and explored the
acceptability and feasibility of potential implementation of this alternative in routine
screening.
Methods
A series of sequential laboratory assays examined the impact of several pre-analytical con-
ditions for obtaining DNA from urine and subsequent HPV detection. Initially, we assessed
the effect of ethylaminediaminetetraacetic acid (EDTA) as a DNA preservative examining
several variables including EDTA concentration, specimen storage temperature, time
between urine collection and DNA extraction, and first-morning micturition versus conve-
nience sample collection. We further evaluated the agreement of HPV-testing between
urine and clinician-collected cervical samples among 95 women. Finally, we explored the
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Results
Our results revealed higher DNA concentrations were obtained when using a 40mM EDTA
solution, storing specimens at 25˚C and extracting DNA within 72 hrs. of urine collection,
regardless of using first-morning micturition or a convenience sampling. We observed good
agreement (Kappa = 0.72) between urine and clinician-collected cervical samples for HPV
detection. Furthermore, urine self-sampling was an affordable method (USD 1.10), well
accepted among cervical cancer screening users, healthcare workers, and decision-
makers.
Conclusion
These results suggest urine self-sampling is feasible and appropriate alternative for HPV-
testing in HPV-based screening programs in lower-resource contexts.
Introduction
Cervical cancer is the second leading cause of cancer deaths in low- and middle-income coun-
tries (LMICs), with almost 285,000 new cases every year [1]. Current screening programs, in
these settings, have low coverage, being 59.7% in Mexico, and even lower in other countries
[2,3]. Cervical screening requires trained personnel and infrastructures to collect cervical sam-
ples, which is not always available in LMICs [4–6]. Furthermore, cultural background alone
can act as a barrier to achieving high screening coverage when patients’ acceptance of pelvic
examination is low [4,5].
Urine self-sampling has been proposed as an alternative primary screening method for
detecting high-risk human papillomavirus (hrHPV), given self-sampling may increase wom-
en’s willingness to participate in screening [3–5]. Previous studies have used specially designed
collection devices with specialized buffers and preservation media, which are costly [7,8], hin-
dering implementation of urine sampling for hrHPV screening in LMICs, where it is most
needed [1,6].
There are several challenges to obtaining proper urine DNA preservation in order to
achieve an easy and affordable method applicable to real-world conditions. Among the main
barriers are: 1) time between sampling and processing, as studies have shown that urine DNA
nucleases reduce concentrations of DNA in urine over time [5,9]; 2) an optimal concentration
of ethylenediaminetetraacetic acid (EDTA) is needed for reducing DNA nucleases activity
[5,7,10]; 3) sample storage temperature has also been shown to affect urine DNA preservation
[9,10]; and 4) it is unclear whether using first-morning micturition is superior to a conve-
nience sample from any time of day [11,12].
It is key to have simple and low-cost urine collection and preservation procedures able to
overcome previously described difficulties that may allow use of self-collected urine samples
for the detection of hrHPV as a primary test for cervical cancer screening [13,14]. hrHPV-test-
ing in urine samples is a non-invasive method that may provide enormous logistical advan-
tages and higher acceptance as compared to samples collected by clinicians during a pelvic
examination. The possibility of using urine for hrHPV-based cervical cancer screening could
PLOS ONE Affordable urine self-sampling method for HPV detection
PLOS ONE | https://doi.org/10.1371/journal.pone.0254946 July 21, 2021 2 / 15
HPV testing supplies. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation and revision of the
manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: JS and ELP have
received funding through their institutions for
research projects from BD Diagnostics Systems,
Roche Molecular Systems, and Roche/Ventana
Medical Systems outside the submitted work. JC
reported receiving grants from Genera Biosystems
and Aventis Pharma; personal fees from Merck and
Co. and Roche; and grants and personal fees from
Qiagen, and participating in the sponsored
speakers’ bureau for Hologic, Gen-Probe, and
Becton Dickinson Systems outside the submitted
work. CW reported receiving research support
from Genera Biosystems, personal fees from
Becton Dickinson, and supplies and equipment
through her institution from Roche Molecular
Systems and Roche/Ventana Medical Systems
outside the submitted work. No other disclosures
were reported.
overcome barriers that limit screening coverage [4,5,15]. It is also important to evaluate the
acceptability of urine self-collection among participants of the targeted cervical cancer screen-
ing program, among health professionals involved in the program and decision-makers of
healthcare-services who are responsible for potential implementation of this procedure within
the cervical cancer screening program.
We aimed to evaluate a low-cost method for urine self-sampling for HPV-testing that could
be potentially translated into clinical practice and public policy, requiring minimum training
among healthcare providers. Additionally, cost, acceptability and feasibility were evaluated as
core elements for implementation.
Materials and methods
Study design
The study was conducted in two phases. During the first phase, we conducted a series of
sequential laboratory evaluations to examine the impact of different pre-analytical conditions
on the DNA concentration of stored urine samples. All these evaluations were performed in a
set of urine samples donated by five volunteer women, aged 25 to 45, postgraduate students
from Mexico City. The second phase was conducted to evaluate the agreement between
hrHPV-testing in urine samples and clinician-collected cervical samples. Finally, we explored
the acceptability, perception of feasibility and costs of urine self-sampling for hrHPV-testing
in cervical cancer screening. The IRB of the National Public Health Institute (INSP) (CI:1417
CB: 1408–2016) approved the first phase protocol. The second phase was conducted within the
FASTER study, reviewed and approved by the IRB of the INSP (Num: 1322–2015 and 1417–
2016), the Mexican regulatory agency Federal Committee for Protection from Sanitary Risks
(COFEPRIS) (163300410A0160/2016), and the Mexico City Ministry of Health (211/001/003/
16); and registered in ClinicalTrials.gov, number: NCT03105856. The objective of the study,
procedures, and possible consequences were explained to potential participants before obtain-
ing written informed consent [16].
First phase
We first evaluated the impact of different EDTA concentrations, and different storage temper-
atures on DNA concentration in urine samples (Fig 1). Five volunteer women were asked to
collect a first-morning, first-void urine sample of ~25ml in each of six different cups, num-
bered from one to six. Cups contained different EDTA concentrations: no EDTA, 10mM and
40mM EDTA. Participants were instructed to store odd-numbered cups at room temperature
and to store even numbered cups in their refrigerator. On the same day, samples were trans-
ported to the laboratory, maintaining assigned storage temperature conditions of each sample
until analysis 24 hours after collection. A total of 30 urine samples of 25ml were evaluated.
A second evaluation working with the same volunteers focused on the best time between
urine collection and DNA extraction, in an attempt to avoid the precipitation of protein crys-
tals, microorganism proliferation and DNA degradation. Participants were asked to collect a
first-morning, first-void urine sample of 25ml each in six different cups of 25ml each, num-
bered from one to six. Three cups contained 10mM EDTA while the other half contained
40mM. Samples were then processed at 24, 48 and 72 hours (Fig 2).
We also determined if a convenience urine sample provided similar or different DNA con-
centration compared to a first-morning micturition. Two samples were collected from each of
the five participants, one from a first-morning micturition and a second one at a convenient
time of the day. Samples were then stored at room temperature until DNA extraction 24 hours
after collection (Fig 3).
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DNA extraction and quantification process
DNA extraction and quantification in all evaluations of the first phase of this work were per-
formed with a similar procedure. All samples were centrifuged at 3000 rpm for 10 minutes, the
pellet was resuspended in 1ml of supernatant and the rest of supernatant was discarded. For
extraction, the Gentra Puregene Cell Kit’s (©Qiagen GmbH, Germany) [17] protocol specified
by the manufacturer was followed. Then, 5.5ml of lysis solution and 30μl proteinase-K (20mg/
ml) were added to the resuspended pellet and later mixed by vortexing for 1 minute. The mix
was then incubated at 55˚C overnight (15 hours), subsequently mixed again for 1 minute and
2ml of protein precipitation solution added and mixed vigorously for 1 minute. Subsequently,
the DNA was quantified by UV absorption using a spectrophotometer (NanoDropTM, Ther-
moFisherScientific) per the manufacturer’s protocol [18].
Fig 1. Overview of collection and management of urine samples to evaluate optimal EDTA concentration and
storage temperature. This evaluation was performed in a set of urine samples from five volunteer women, who
collected a first-morning, first-void urine sample, in six different cups (25ml each). Cups contained different EDTA
concentrations added prior to urine addition: No EDTA, 10mM and 40mM EDTA. Half of the samples (the ones
labeled with odd numbers) were stored at room temperature and those with even numbers were stored in the fridge at
~4˚C. DNA extraction and quantification were performed 24 hours after collection.
https://doi.org/10.1371/journal.pone.0254946.g001
Fig 2. Overview of urine sample collection and processing of second evaluation. Separating samples into two
groups with different EDTA concentrations, further divided to examine different lengths of time from urine specimen
collection to time of specimen processing. This evaluation was performed as a set of urine samples from five volunteer
women, who collected a first-morning, first-void urine sample, in six different cups (25ml each). Three cups contained
10mM EDTA while the other three cups contained 40mM. Samples were then processed at 24, 48 and 72 hours as
shown.
https://doi.org/10.1371/journal.pone.0254946.g002
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Second phase
We evaluated the agreement performance of our urine sampling storage and processing
method among participants of the FASTER Study; using urine samples collected by 95 subjects
who were randomly selected among women attending routine cervical cancer screening in a
primary health-care clinic in Tlalpan Health Jurisdiction, Mexico City [16]. At the time of
appointment for cervical cancer screening, immediately preceding the clinician-collected cer-
vical sample, all women were instructed to collect a urine sample in the restroom of the health-
care center. The urine samples were stored according to the optimal method derived from the
first phase of the study. These paired samples, standard clinician-collected cervical samples
and urine samples- were processed using an automated PCR platform (BD ViperTM System)
[19], which has an integrated module for protein denaturation, DNA extraction and HPV
genotyping.
Qualitative data assessing the beliefs and attitudes of patients and health care personnel was
collected from July to August 2018 to obtain information about current cervical cancer screen-
ing and self-collected urine. A group of three interviewers carried out interviews in different
health-care centers of the Tlalpan Health Jurisdiction, Mexico City, ensuring participants’ pri-
vacy and comfort. Additionally, semi-structured interviews were performed with14 partici-
pants of the FASTER study (not included in the aforementioned 95 subjects) to evaluate the
acceptability and feasibility as a potential implementation of urine self-sampling in routine
cervical cancer screening conditions.
In addition, nine health-care professionals of primary health-care centers and nine deci-
sion-makers who witnessed the use of the urine self-sample alternative among participants of
the FASTER Study were also interviewed. Interviews with consenting participants took place
in private rooms at the health-care centers. Interview guides focused on attitudes, acceptability,
and feasibility of urine sampling for primary hrHPV-testing in cervical cancer screening.
Field-notes were taken during interviews using open-ended questioning. All interviews were
audio-recorded. Finally, we carried out an exploratory micro-cost analysis including the sup-
plies necessary for obtaining a sample at retail pricing.
Data analysis
For each evaluation in phase I, descriptive analyses were performed to summarize DNA con-
centration values obtained from different storage conditions. The Wilcoxon test for non-
parametric statistics was performed in paired samples to compare DNA median concentra-
tions according to different EDTA concentrations (40mM, 10mM and no EDTA), storage
Fig 3. Overview of sample collection and processing for the third evaluation. Two samples were collected from each
of the five participants, one from a first-morning micturition and a second one at a convenient time of the day which
differed between women and was not prespecified. Samples were then stored at room temperature until DNA
extraction 24 hours after collection.
https://doi.org/10.1371/journal.pone.0254946.g003
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temperatures (4˚C and 25˚C), duration between sample collection and extraction (24h, 28h,
72h) and different sample collection times (first-morning micturition and convenience
sample).
For phase II, we performed descriptive analyses for specific HPV genotype detection and
examined correlations between HPV types detected in cervical and urine samples using
Cohen’s Kappa coefficient. Stata Corp LLC Stata1 Version 14.2 was used for these
evaluations.
For the qualitative analysis, we identified emerging themes related to acceptance (ease and
comfort) and feasibility perception; Data interpretation was performed by grouping relevant
information by category, following standard approaches [20].
Results
Optimal EDTA concentration and storage temperature
The mean concentration of DNA obtained from samples stored either at room tempera-
ture (�25˚C) or 4˚C for a maximum of 72 hours was determined. Specimens stored at
�25˚C without EDTA, 10 mM EDTA or 40 mM EDTA yielded mean concentrations of
30.4, 15.8 and 41.1 ng/μl respectively. The highest EDTA concentration (40mM) offered
significantly higher DNA concentrations compared to 10mM EDTA (p = 0.043) and with-
out EDTA (p = 0.06).
Similarly, specimens stored at 4˚C, without EDTA, 10mM EDTA or 40mM EDTA yielded
mean concentrations of 8.6, 6.0, and 13.0 ng/μl, respectively. Again, a high concentration of
EDTA yielded better DNA concentrations against 10mM EDTA (p = 0.043) and without
EDTA (p = 0.043).
The best storage temperature was 25˚C compared to 4˚C, regardless of EDTA concentra-
tion: 30.4 vs. 8.6 ng/μl without EDTA; 15.8 vs. 6.0 ng/μl with 10mM EDTA; and 41.1 vs. 13.0
ng/μl with 40mM EDTA (p = 0.041, p = 0.043, p = 0.043, respectively) (Fig 4). Regarding DNA
purity as determined by the 260/280 absorbance (nanometers;nm) ratio for samples preserved
at 25˚C (median = 1.82, p25 = 1.81, p75 = 1.89) was better than in samples stored at 4˚C
(median = 1.47, p25 = 0.95, p75 = 1.75). A 260/280 ratio of ~1.8 is generally accepted as “pure”
for DNA. On the other hand, a 260/280 ratio <1.6 indicates probable contamination from
residual phenol, guanidine, proteins or other reagent used in the extraction protocol [21].
Addicionaly the refrigerated urine samples also showed macroscopic crystalline forms which
were absent in samples stored at room temperature.
Effect of time from collection to processing
We observed that the time elapsed between sample collection and processing influenced a
lower DNA concentration. The median DNA concentrations of samples stored in 10mM
EDTA processed at 24, 48 and 72 hours were 88.4, 75.0 and 51.9 ng/μl, respectively. The
median DNA concentrations of samples stored in 40mM EDTA were 83.0, 77.4 and 68.9 ng/μl
for samples processed at 24, 48 and 72 hours, respectively (Fig 5).
First-morning urine self-sampling vs. convenience micturition
No significant differences were observed between DNA concentrations from first morning
micturition samples [median = 79.5 ng/μl, (p25 = 65.3, p75 = 91.2)] compared to a micturition
collected at any time of the day [median = 60.4 ng/μl, (p25 = 53.3, p75 = 67.1)] (p = 0.11 for
Wilcoxon test) when stored at room temperature with 40mM EDTA.
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Fig 5. DNA concentration of samples processed at different times after sample collection. The top of the
box represents the upper quartile (p75), the bottom the lower quartile (p25), and the line the median (p50), the median
is displayed above the line. The upper and lower whiskers extend to 1.5 times the interquartile range, while the dots
mark the largest and smallest values of the distribution.
https://doi.org/10.1371/journal.pone.0254946.g005
Fig 4. DNA concentration in samples stored in different EDTA concentrations and temperatures. The top of the
box represents the upper quartile (p75), the bottom the lower quartile (p25), and the x-patterned line the median (p50),
the median is identified above the line. The upper and lower whiskers extend to 1.5 times the interquartile range. The
best DNA concentrations resulted from EDTA at 40mM, both at 25˚C and 4˚C. The best storage temperature was
25˚C compared to 4˚C, regardless of EDTA concentration. DNA extraction and quantification presented for this
particular experiment were performed 24 hours after collection.
https://doi.org/10.1371/journal.pone.0254946.g004
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Correspondence of specific hrHPV detection in urine samples vs. cervical
samples
We evaluated the agreement of specific hrHPV detection on 95 paired urine samples com-
pared to clinician-collected cervical samples. We used urine samples preserved with the opti-
mal collection method based on the results of our initial studies to achieve optimization. The
general characteristics of the participants in this paired comparison are presented in S1 Table
of the Supporting information file. The mean age of women was 41.5±9.9 years, 43.2% were 20
to 39 years old, 35.8% were 40 to 49 years old and 21.1% were 50 years old or more. The major-
ity were married or cohabitating (74.7%), 40% reported having had 1 sexual partner in their
lifetime whereas 30.5% had had between 2 and 3 partners.
Among the 95 paired samples, all urine and cervical samples had the amplification control
target of the β-globin gene detected. In cervical samples, the prevalence of hrHPV was 13.7%,
of HPV16 1.1% and 0% for HPV18. Urine samples had a prevalence of hrHPV of 22.1%, 3.2%
for HPV16, and 0% positive samples for HPV18.
We observed that all 13 hrHPV positives identified by the HPV testing in cervical samples
were successfully detected in urine samples. The specific hrHPV types detected in cervical
samples, were also detected in urine samples. In addition, we detected a case with HPV 45 and
another with HPV 52 in urine that were not detected in cervical samples. Among these paired
samples we observed an acceptable agreement of hrHPV detection in paired urine and cervical
samples as shown by a Kappa value of>0.6 (Table 1).
Acceptability, feasibility and costs of urine self-sampling
Fourteen women were subjected to interview. The majority (64%) had completed basic
or middle-level education; half of them lived with a partner and had at least one child. All
women stated that urine self-sampling was a more comfortable and acceptable method of cer-
vical cancer screening compared to clinician-directed cervical sampling. They felt that collect-
ing a urine sample was an easy and common procedure, and women were familiar with
routine urinalysis. Eliminating the shame associated with clinician-directed cervical sampling,
with the added advantages of a substantially faster and more comfortable process along with
the possibility of collecting urine at home made the future use of urine samples for the detec-
tion of cervical cancer a very attractive alternative.
Table 1. Type specific HPV positivity differences between urine and cervical samples.
Cevical sample n (%) Urine sample n (%) Kappa values
hrHPV+ 13 (13.7) 21 (22.1) 0.72
HPV16+ 1 (1.1) 3 (3.2) 0.49
HPV18+ 0 0 -
HPV45+ 0 1 (1.1) 0.00
HPV31+ 3 (3.2) 4 (4.2) 0.85
HPV51+ 1 (1.1) 3 (3.2) 0.49
HPV52+ 0 1 (1.1) 0.00
Pool 1a 2 (2.1) 3 (3.2) 0.79
Pool 2b 6 (6.3) 8 (8.4) 0.84
Pool 3c 2 (2.1) 5 (5.3) 0.56
a Pool 1: HPV33/58
b Pool 2: HPV56/59/66
c Pool 3: 35/39/68.
https://doi.org/10.1371/journal.pone.0254946.t001
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We also interviewed five physicians, three nurses and one social worker, ages 34 to 62, of
which 89% were women. All interviewed agreed that urine collection was a more straightfor-
ward strategy for cervical cancer screening than sampling collection requiring a pelvic exami-
nation. Furthermore, they felt that urine analysis was an excellent opportunity for women to
be able to obtain the sample in their own homes and deliver it to their healthcare centers.
Moreover, 78% of physicians considered that urine collection may be implemented as a cervi-
cal cancer screening strategy given the convenience and simplicity of the procedure.
Of nine policy decision-makers interviewed, 40% were women, 44% had specialty or post-
graduate studies, with several years of experience in the field of preventive medicine. Six of
them were heads of departments (i.e., nursing, preventive medicine, cancer screening, epide-
miology). All considered urine self-sampling as an alternative that could overcome barriers
such as the discomfort associated with pelvic examination and cervical sampling, with a good
possibility for its implementation in healthcare centers at no additional cost.
The preliminary cost of a urine sample was estimated at USD $1.10, the details of prices are
listed in Table 2.
Discussion
Our results suggest that DNA for HPV-testing can be obtained from urine samples with only a
simple solution of 40mM EDTA and can be stored at room temperature up to 72 hours before
processing. Urine HPV-testing, employing this low-cost sampling procedure, offers good
agreement with paired clinician-collected cervical samples. Furthermore, urine self-sampling
seems to be highly acceptable and is an affordable method with good potential for implementa-
tion within the cervical cancer screening program in Mexico.
Vorsters et al. previously tried a new in-house buffer for urine samples destined for HPV
detection that contained bovine serum albumin, a microbicide and a fungicide in addition to
the chelating agent [7]. Although this might be a suitable buffer, it has been previously
reported that only adding EDTA as a chelating agent may be sufficient for good DNA preser-
vation [5,7,10]. Our findings are consistent with these reports as we were able to obtain opti-
mal results using only 40mM EDTA, which can be expected to keep costs low.
Room temperature was not suitable for storing urine samples in the absence of EDTA. In
contrast, studies by Bosschieter et al., Cannas et al. and Augustus et al. found that appropriate
DNA concentrations could be extracted from urine stored at room temperature for several
days as long as EDTA was added [9,10,22]. In our study, the DNA quantification from urine
samples stored at room temperature (25˚C) was superior to refrigeration at 4˚C (p = 0.004).
Table 2. Supplies for urine self-sampling.
Supplies Unit costs�
Urine collection cup (100ml) $0.35
EDTA Buffer $0.02
Sterile Conic Tube (50ml) $0.38
Cell lysis $0.14
Semiautomatic micropipette and tips $0.05
Sterile Nitrile gloves $0.01
Cryovials 2mL (Sterile) $0.15
Packaging and storage $0.03
Total cost per one urine sample $1.13
�Costs are expressed in USD, exchange rate as of June 2020.
https://doi.org/10.1371/journal.pone.0254946.t002
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These findings are similar to those of Augustus et al., who found that, when using preserva-
tives, urine samples stored at room temperature and at 30˚C showed higher concentrations of
DNA and higher stability over time when compared to samples stored at 4˚C [22]. Further-
more, as demonstrated by a higher absorbance ratio 260/280, samples stored at room tempera-
ture had a higher purity. These findings in refrigerated samples could be associated with the
presence of previously mentioned crystalline formations. A previous study also reported that
crystalline formations occurred when refrigerating urine and after microscopic examination
identified them as urate and phosphate crystals [23]. They linked the presence of these crystals
in urine to lower DNA concentrations and lower 260/280 ratios, suggesting that these crystals
interfered with DNA purification. Further studies could help establish how different tempera-
tures affect DNA concentrations, as there are geographical regions in which room temperature
will likely exceed 30˚C. More studies could also help determine the role of crystals in DNA
purification from urine samples.
Regarding time from collection to processing, we found that processing within the first 72
hours yielded DNA concentrations appropriate for HPV testing. These results are consistent
with previous findings documenting that DNA concentration decreases over time [5,9]. We
did not find any statistically significant difference when comparing first-morning urine against
a convenience sample, which confirms findings from previous authors [11,12].
The cost estimate of a urine sample in our study ~ USD $1.10, was much less than currently
available commercial kits [24,25]. Without considering the cost of handling and processing
samples for HPV screening, one cervical sample vial costs USD $2.42, plus the additional cost
of collecting the cervical sample (approximately USD $2.00) [26]. We are not aware of studies
estimating the cost of a urine test and comparing it to a standard detection test. Nevertheless,
our findings show a lower cost for obtaining a urine sample versus a clinician-collected cervi-
cal sample, which offers an additional advantage of this alternative, making it more attractive
and promising. Based on our results, a simple and affordable collection and storage procedure
is possible and can be proposed for potential use within the cervical cancer screening program.
hrHPV detection in urine samples has previously been reported with acceptable agreement
compared to clinician-directed cervical samples [12–14,23,27]. However, as previously docu-
mented by Van Keer et al. [28], urine samples detected a larger proportion of HPV infections
than cervical samples. This difference could be due to the fact that urine contains sloughed
cells and mucus from many parts of the genitourinary tract that contaminate the first-void
urine fraction, whereas cervical samples are largely cervical cells. Thus, urine self-samples
could generate an increase in false positives; triage alternatives should be used to improve
screening effectiveness.
We defined the degree of agreement according to the guidelines outlined by Landis and
Koch in 1977:< 0 no agreement, 0.01 to 0.2 slight agreement, 0.21 to 0.40 fair agreement, 0.41
to 0.60 moderate agreement, 0.61 to 0.80 substantial agreement and 0.8 to 1.0 almost perfect
agreement [29]. In our study the overall Kappa value for HPV was 0.72, with a Kappa for
HPV16 of 0.49, indicating at least a moderate agreement. The agreement between urine and
HPV samples for HPV detection is consistent with previously reported Kappa values, which
vary from 0.35 up to 0.96 [12,14,27,28]. All HPV infections observed in cervical samples were
detected in urine.
Our qualitative analysis reveals that women consider acceptable urine self-sampling and
preferred this because of characteristics such as comfort, simplicity and speed of collection.
Our participants consider it could be a feasible strategy for implementation at their healthcare
centers. These findings are similar to those reported in previous studies, highlighting the
advantages of urine collection as a method for HPV DNA detection [13,30–32]. Sellors et al. in
Canada, reported acceptability of 98.4% for urine sample collection compared to 79% for
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cervical samples [33]. A study by Sy et al. done on Micronesian women described urine sam-
pling as more comfortable compared to cervical sampling, by 95% and 82%, respectively [32],
while another study reported that urine collection reduced fear and anxiety in participants,
proposing it as an attractive alternative that could become a routine procedure [30]. Most
healthcare professionals we interviewed (78%) were involved in cancer screening programs
and they considered it feasible to implement urine collection as a good alternative for HPV-
testing. To our knowledge, this evaluation among healthcare professionals and personnel
responsible for cervical cancer screening program has not been previously reported.
In accordance with earlier reports, we believe that the urine self-sampling method has the
potential to impact screening coverage [31,34]. In high-income regions such as France, a study
observed that urine samples for HPV-testing could become a relevant method for providing
screening to underserved women in rural areas and to women who refuse the more invasive
sampling required for cervical cytology testing. This would lead to an increase in coverage and
timely treatment of high-grade lesions, potentially diminishing mortality rates and associated
treatment costs of cervical cancer [34].
One of the strengths of our study was our focus on real-world applicability. Phase one
focused on pre-analytical conditions geared towards techniques most likely to be applied to
our environment with favorable results, such as room temperature storage, processing within
72 hours, and use of a simple EDTA-based solution for preservation. Furthermore, the second
phase, albeit with a small number of participants, was executed applying the lessons learned
during phase one, with valuable input on acceptability and feasibility from both patients and
healthcare professionals actively involved in cervical cancer early detection programs in
Mexico.
However, as mentioned above, an important limitation of this study was the small sample
size of the second phase which was descriptive to support future appropriately powered inves-
tigations. Our main objective was to provide early evidence about whether urine sample using
a new low-cost method could be successful in subsequent diagnostic trials.
Nevertheless, acknowledging that the second phase of our study was to evaluate the agree-
ment between hrHPV-testing in urine samples and regular cervical samples, we performed a
post-hoc power calculation to detect differences in HPV detection for paired samples. All
HPV positives cases identifying in cervical samples were successfully detected in urine samples
with a power of 81.79%, with an alpha of 0.05 using paired samples from 95 participants.
This study showed only the concordance between urine and cervical sample for HPV detec-
tion. For HPV tests using self-collected urine to be clinically applied, further investigation will
be required to measure the clinical performance of HPV tests with evaluation of CIN2
+ detection.
Overall, we found urine-self sampling to be less expensive than cervical samples, was able to
overcome technical and cultural barriers, and had an acceptable agreement with clinician-col-
lected cervical sampling in the detection of HPV. Our findings and those of previous studies,
support proposing urine as promising alternative for increasing coverage of cervical cancer
screening programs worth further evaluation. Our findings also suggest that a urine sampling
strategy is worth further evaluation as it is also seen as feasible by healthcare professionals and
accepted by patients for implementation as part of the cervical cancer screening program in
Mexico.
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